Tempo Therapeutics, Inc.

Based in California, US, founded in 2014, Tempo Therapeutics, Inc. operates as a biotechnology research company that develops and manufactures tissue engineering solutions for regenerative medicine using its Microporous Annealed Particle technology. The company was co-founded by Donald Griffin and Westbrook Weaver. Currently, Eric Richman serves as the CEO as of 2026.

In August 2026, Tempo Therapeutics, Inc. raised USD 14 million in venture debt funding led by Galaxy-Sirius Partners, with participation from Gideon Strategic Partners, Mesa Verde Venture Partners, YK Bioventures, and Johnson & Johnson Innovation. The firm pioneers tissue engineering biotechnology using its proprietary MAP (Microporous Annealed Particle) material science technology. MAP enables the creation of injectable porous scaffolds for regenerative medicine, modulating patients' immune cells for regenerative responses.

Their biosurgery products address soft tissue reconstructions, improving outcomes by promoting tissue strength and function. Additionally, Tempo develops novel therapies in various therapeutic areas using MAP technology.   The company plans to use the August 2026 funding to support its lead surgical reconstruction program through potential regulatory clearance and commercialization while generating clinical data to evaluate additional applications of the MAP platform, including aesthetic dermatology.